类风湿关节炎TNFi失败后循环vs换药经济评价的系统综述
该系统综述纳入7篇文献共19项比较,评估类风湿关节炎患者初始TNFi失败后循环使用TNFi与换用不同作用机制药物的经济分析模型与质量。多数模型采用终身时间范围、支付方视角、6个月周期,以ACR改善标准衡量疗效。换药策略相比循环策略的增量成本效果比中位数为每质量调整生命年70,332美元。
要点
- 7篇文献中仅3篇CHEERS清单评分≥16/24,报告质量参差。
- 换药vs循环策略的ICER中位数为70,332美元/QALY。
- 11项比较中7项显示利妥昔单抗比TNFi更有效且更便宜。
核心结论
- 模型设计、关键假设和模型结构的差异对各项研究结论有重大影响。
- 尽管存在多种报告标准,TNFi失败后循环vs换药策略的经济评价方法学仍需进一步统一。
研究设计与样本
- 系统综述检索电子数据库、灰色文献及纳入文献参考文献,截至2017年7月。
- 两名评价者独立筛选文献,采用CHEERS清单评估报告质量,提取建模方法学数据。
- 共纳入7篇文献,包含19项比较。
主要发现
- 3项研究在CHEERS清单(满分24分)上评分≥16分。
- 多数模型采用终身时间范围、支付方视角、6个月周期长度,以ACR改善标准衡量疗效。
- 在成本-效用比较中,换药vs循环策略的增量成本效果比中位数为每质量调整生命年70,332美元。
- 11项比较中7项显示利妥昔单抗比TNFi更有效且更便宜;阿巴西普(静脉)相比TNFi的成本效果劣于利妥昔单抗。
- 敏感性分析中常见的影响参数为利妥昔单抗给药方案、疾病进展假设和效用值估计。
临床怎么用
- 临床决策参考时需注意各经济评价的模型结构、关键假设和赞助来源差异对结论的影响。
- 利妥昔单抗在多数比较中显示比TNFi更具成本效果优势,但需结合具体临床情境解读。
局限性
- 存在透明度和研究赞助方面的潜在偏倚来源。
- 各研究设计、关键假设和模型结构差异大,影响结论可比性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To systematically review the modeling approaches and quality of economic analyses comparing cycling tumor necrosis factor inhibitors (TNFi) to swapping to a therapy with a different mode of action in patients with rheumatoid arthritis whose initial TNFi failed. METHODS: We searched electronic databases, gray literature, and references of included publications until July 2017. Two reviewers independently screened citations. Reporting quality was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Data regarding modeling methodology were extracted. RESULTS: We included 7 articles comprising 19 comparisons. Three studies scored ≥16 of 24 on the CHEERS checklist. Most models used a lifetime horizon, took a payer perspective, employed a 6-month cycle length, and measured treatment efficacy in terms of the American College of Rheumatology improvement criteria. We noted possible sources of bias in terms of transparency and study sponsorship. In the cost-utility comparisons, the median incremental cost-effectiveness ratio was US $70,332 per quality-adjusted life-year for swapping versus cycling strategies. Rituximab was more effective and less expensive than TNFi in 7 of 11 comparisons. Abatacept (intravenous) compared to TNFi was less cost-effective than rituximab. Common influential parameters in sensitivity analyses were the rituximab dosing schedule, assumptions regarding disease progression, and the estimation of utilities. CONCLUSION: Differences in the design, key assumptions, and model structure chosen had a major impact on the individual study conclusions. Despite the existence of multiple reporting standards, there continues to be a need for more uniformity in the methodology reported in economic evaluations of cycling versus swapping strategies after TNFi in patients with rheumatoid arthritis.
引用
- Karpes Matusevich AR, Suarez-Almazor ME, Cantor SB, et al. Systematic Review of Economic Evaluations of Cycling Versus Swapping Medications in Patients With Rheumatoid Arthritis After Failure to Respond to Tumor Necrosis Factor Inhibitors. Arthritis Care Res (Hoboken). 2020. PMID: 30801951. doi:10.1002/acr.23859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。